Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma
- Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease
- Preparing for Phase III development following promising data showing reduced fractures in affected children
Stockholm, Sweden, February 10, 2026 – BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, today announced the appointment of seasoned biotech entrepreneur Hans Schambye, MD, PhD, as its new Chief Executive Officer. Hans currently serves on the Board of Directors of BOOST Pharma and has transitioned with immediate effect into his new role as Chief Executive Officer on a full-time basis.
